NovoCure (NVCR) Free Cash Flow Growth (1y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -1.82% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 226.77% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 9.73% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -51.69% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -109.40% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 133.09% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 363.84% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 108.16% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 29.12% |
| 10 | NovoCure | 1.90 Bn | 1.47 Bn | 135.13 Mn | 59.66% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 59.66% |
| Dec 31, 2025 | -84.78% |
| Sep 30, 2025 | 4,959.61% |
| Jun 30, 2025 | -62.71% |
| Mar 31, 2025 | -6.73% |
| Dec 31, 2024 | 42.03% |
| Sep 30, 2024 | 98.84% |
| Jun 30, 2024 | 55.62% |
| Mar 31, 2024 | -90.04% |
| Dec 31, 2023 | -110.88% |
| Sep 30, 2023 | -258.92% |
| Jun 30, 2023 | -355.08% |
| Mar 31, 2023 | -159.85% |
| Dec 31, 2022 | -7,898.46% |
| Sep 30, 2022 | -20.78% |
| Jun 30, 2022 | -50.62% |
| Mar 31, 2022 | -163.63% |
| Dec 31, 2021 | -99.73% |
| Sep 30, 2021 | -25.13% |
| Jun 30, 2021 | 149.88% |
| Mar 31, 2021 | 1,294.72% |
| Dec 31, 2020 | 1,121.45% |
| Sep 30, 2020 | 131.06% |
| Jun 30, 2020 | 41.34% |
| Mar 31, 2020 | 82.61% |
| Dec 31, 2019 | -73.99% |
| Sep 30, 2019 | 184.69% |
| Jun 30, 2019 | 179.90% |
| Mar 31, 2019 | 62.19% |
| Dec 31, 2018 | 280.69% |
| Sep 30, 2018 | 113.93% |
| Jun 30, 2018 | -33.53% |
| Mar 31, 2018 | 37.15% |
| Dec 31, 2017 | 42.04% |
| Sep 30, 2017 | 105.69% |
| Jun 30, 2017 | 80.30% |
| Mar 31, 2017 | 12.63% |
| Dec 31, 2016 | 47.22% |
| Sep 30, 2016 | -51.11% |
| Jun 30, 2016 | -26.93% |
| Mar 31, 2016 | -9.99% |
| Dec 31, 2015 | -50.79% |